Showing 2171-2180 of 5771 results for "".
- Ribomic Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet AMDhttps://modernod.com/news/ribomic-announces-first-injection-in-the-phase-2-clinical-trial-of-rbm-007-tofu-study-in-subjects-with-wet-amd/2477304/Ribomic announced that first patient has received injection in the phase 2 trial of RBM-007 for the treatment of wet age-related macular degeneration (AMD) in the United States. The first site started enrollment at the end of December 2019 and five sites are now active across the United States.</
- Palatin Technologies Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial With PL9643https://modernod.com/news/palatin-technologies-announces-first-patient-enrolled-in-dry-eye-disease-phase-2-clinical-trial-with-pl9643/2477303/Palatin Technologies announced that it has enrolled the first patient in a phase 2 clinical trial of topical PL9643, a melanocortin 1/5 receptor (MC1/5r) agonist, for the treatment of dry eye disease (DED). “We are pleased to initiate this phase 2 study of PL9643 exploring treatment
- Fifteenth Annual Eyes on Capitol Hill Advocacy Eventhttps://modernod.com/news/fifteenth-annual-eyes-on-capitol-hill-advocacy-event/2477302/Prevent Blindness will be holding its 15th annual “Eyes on Capitol Hill” advocacy day on February 26, 2020, in Washington, D.C. The annual program provides those from across the United States the opportunity to meet with Congressional and Senate members, and their staff, to discuss vision issues
- Kodiak Sciences Announces Additional Data from Ongoing Phase 1b Study of KSI-301 in Patients With Retinal Diseaseshttps://modernod.com/news/kodiak-sciences-announces-additional-data-from-ongoing-phase-1b-study-of-ksi-301-in-patients-with-retinal-diseases/2477282/Kodiak Sciences announced promising safety, efficacy, and durability data from the ongoing phase 1b study of its investigational therapy KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet age-related macular degener
- Staar Surgical Announces Strategic Cooperation Agreement with Senshinkai Eye Institute in Japanhttps://modernod.com/news/staar-surgical-announces-strategic-cooperation-agreement-with-senshinkai-eye-institute-in-japan/2477276/Staar Surgical announced that it entered a strategic cooperation agreement with Senshinkai Eye Institute (SEI), an eye care group with five locations in Japan. The agreement includes volume commitments for the company’s implantable collamer lenses (ICLs), ICL surgeon training and certification, t
- Verana Health Acquires PYA Analytics; Announces $100 Million Financinghttps://modernod.com/news/verana-health-acquires-pya-analytics-announces-100-million-financing/2477275/Verana Health announced that it has acquired the assets of data science company PYA Analytics (PYAA). Based in Knoxville, Tennessee, PYAA specializes in large-scale data architecture solutions. Terms of the deal were not disclosed. PYAA was founded in 2013 by scientists and engineer
- Staar Surgical Announces the EVO Implantable Lens US Clinical Trial is Underwayhttps://modernod.com/news/staar-surgical-announces-the-evo-implantable-lens-us-clinical-trial-is-underway/2477273/Staar Surgical announced the first patient was implanted in the company’s US human clinical study for its EVO ICL family of lenses. The investigational study, “A Multicenter Clinical Evaluation of the EVO/EVO+ Visian Implantable Collamer Lens,” will be conducted at more than a dozen ophthalmology
- Aerie Pharmaceuticals Announces Appointment of Michelle Senchyna, PhD, as Vice President, Clinical Development and Medical Affairshttps://modernod.com/news/aerie-pharmaceuticals-announces-appointment-of-michelle-senchyna-phd-as-vice-president-clinical-development-and-medical-affairs/2477271/Aerie Pharmaceuticals announced the appointment of Michelle Senchyna, PhD, as Vice President, Clinical Development and Medical Affairs, reporting to David A. Hollander, MD, MBA, Aerie’s Chief Research & Development Officer. Dr. Senchyna will lead and direct the clinical development and
- Midwest Vision Partners Announces Partnership with Specialty Eye Institutehttps://modernod.com/news/midwest-vision-partners-announces-partnership-with-specialty-eye-institute/2477268/Midwest Vision Partners (MVP), an eye care management services organization backed by private equity firm Alpine Investors, has announced its partnership with Specialty Eye Institute (SEI). Terms
- Bausch Health and Clearside Biomedical Announce Publication of Pivotal Phase 3 Data on Xiperehttps://modernod.com/news/bausch-health-and-clearside-biomedical-announce-publication-of-pivotal-phase-3-data-on-xipere/2477264/Bausch Health Companies and Clearside Biomedical announced that results from the randomized, controlled, double-masked phase 3 clinical trial (PEACHTREE study) of Xipere (triamcinolone acetonide suprachoroidal injectable suspension), have been published in Ophthalmology.1 Xiper